Lower Urinary Tract Symptoms in Parkinson Disease: Adjust the Dopamine or Treat the Bladder
A woman's worsening urgency could be ordinary overactive bladder or a dopaminergic problem wearing a bladder's clothing. Which one it is changes whose prescription gets adjusted first.
Colette F., a 68-year-old woman who spends most weekday afternoons in her daughter's backyard garden with her two grandchildren, was diagnosed with Parkinson disease five years ago, a right-hand resting tremor that first showed up while she was weeding, and has taken carbidopa-levodopa for three of those years at a dose unchanged for the last eight months, well enough controlled that the tremor rarely interferes with the raised beds she still tends herself. Over the past two months she has developed urgency severe enough to send her inside from the garden with little warning, along with nocturia waking her three to four times a night — new enough, and disruptive enough, that she raised it unprompted at what was meant to be a routine movement-disorders follow-up, apologizing for bringing up 'a bladder thing' at what she assumed was the wrong kind of appointment.
Her carbidopa-levodopa dose has been unchanged for eight months, and her motor symptoms remain well controlled on today's exam, which argues against a simple wearing-off phenomenon explaining the new urinary symptoms. But lower urinary tract symptoms in Parkinson disease are not always what an isolated overactive bladder would produce: the same nigrostriatal dopaminergic pathway that governs her motor symptoms also modulates the pontine micturition center by way of the periaqueductal grey, and a genuine dopaminergic contribution to bladder urgency is a real, if underrecognized, presentation distinct from age-related detrusor overactivity happening to occur in someone who also has Parkinson disease. Peyronnet et al.'s retrospective cohort of fifty Parkinson patients given mirabegron — mean age 74, just over half of them already failed on anticholinergics — reported symptom improvement in half and no cognitive changes, which is the reassurance that matters in a population the field handles carefully. At 68 and anticholinergic-naive, Colette is an easier case than that cohort's average rather than a harder one. Her post-void residual is the number worth pausing on: 35mL, entirely normal, which is an awkward finding to sit underneath a dopaminergic voiding disturbance severe enough to be driving symptoms this new and this disruptive.
Movement disorders and urology joint clinic
I'd look at her dopaminergic regimen before reaching for a bladder-specific drug. The same pathway driving her motor control also modulates bladder urgency signaling, and her symptoms are new enough, and specific enough, that a dopaminergic contribution deserves real consideration rather than defaulting straight to overactive bladder just because urgency is the presenting complaint.
The timing works against that read as much as the exam does. Her dose has been stable eight months; the urgency started two months ago. If the dopaminergic pathway were driving this, I'd expect her bladder to have drifted along with her motor symptoms rather than arriving on its own six months after anything last changed.
I'd start mirabegron directly. Peyronnet's cohort showed real symptom improvement with no reported cognitive changes, which matters given how much the field worries about anticholinergics in this population — and it treats her actual presenting complaint without requiring us to first resolve a harder mechanistic question.
I don't think we need to fully resolve which mechanism is driving this before choosing a first step, and mirabegron is a reasonable one regardless of the answer — it treats the bladder directly without foreclosing a later dopaminergic adjustment if this doesn't improve.
What I'd add is a real timeline for reassessment, since if her urgency doesn't respond to a bladder-directed drug at all, that itself becomes evidence toward Dr. Osei's dopaminergic hypothesis, worth revisiting with her movement disorders team rather than escalating bladder therapy further on a mechanism that may not be the real driver.
Agreed: start mirabegron 25mg for her urinary symptoms, hold her dopaminergic regimen unchanged, reassess at 6 weeks.
Not agreed: the neurologist would have preferred adjusting her carbidopa-levodopa timing first as a genuine diagnostic test of the dopaminergic hypothesis, and views deferring that to a second step as leaving a real possibility unexplored — accepted as the group's practical starting point, with an explicit agreement to revisit the dopaminergic question directly if mirabegron doesn't meaningfully help.